Evommune, Inc.
Evommune, Inc.
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Financial Statements
Values in Millions ($) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Financial statements beyond 3 years are for subscribers only. Unlock 17+ years of income statements, balance sheets, and cash flow statements Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|
Assets | |||||||||
Assets Current | |||||||||
Cash And Cash Equivalents At Carrying Value | 60 | 48 | 44 | 27 | |||||
Short Term Investments | 141 | 163 | 105 | 49 | |||||
Prepaid Expense And Other Assets Current | 3 | 4 | 4 | 6 | |||||
Assets Current | 204 | 216 | 153 | 82 | |||||
Operating Lease Right Of Use Asset | 8 | 8 | 1 | 0 | |||||
Property Plant And Equipment Net | 2 | 2 | 1 | 1 | |||||
Long Term Investments | 87 | 96 | 67 | - | |||||
Restricted Cash Noncurrent | 1 | 1 | 1 | 1 | |||||
Other Assets Noncurrent | 0 | 0 | 0 | 0 | |||||
Assets | 302 | 322 | 225 | 85 | |||||
Liabilities And Stockhold… | |||||||||
Liabilities Current | |||||||||
Accounts Payable Current | 5 | 4 | 8 | 4 | |||||
Accrued Liabilities Current | 11 | 5 | 10 | 6 | |||||
Operating Lease Liability Current | 1 | 1 | 0 | 0 | |||||
Other Liabilities Current | 1 | 1 | 0 | 0 | |||||
Liabilities Current | 17 | 11 | 18 | 10 | |||||
Other Liabilities Noncurrent | - | - | - | 0 | |||||
Operating Lease Liability Noncurrent | 6 | 7 | 1 | - | |||||
Finance Lease Liability Noncurrent | - | 1 | 0 | - | |||||
Liabilities | 24 | 18 | 19 | 11 | |||||
Temporary Equity Carrying Amount Attributable To P… | - | - | 0 | 257 | |||||
Stockholders Equity | |||||||||
Common Stock Value | 0 | 0 | 0 | 0 | |||||
Additional Paid In Capital Common Stock | 553 | 547 | 427 | 10 | |||||
Retained Earnings Accumulated Deficit | -275 | -243 | -221 | -193 | |||||
Stockholders Equity | 278 | 305 | 206 | -183 | |||||
Liabilities And Stockholders Equity | 302 | 322 | 225 | 85 | |||||
Temporary Equity Par Or Stated Value Per Share | - | - | 0 | 0 | |||||
Temporary Equity Shares Authorized | - | - | 10 | 158 | |||||
Temporary Equity Shares Issued | - | - | 0 | 158 | |||||
Temporary Equity Shares Outstanding | - | - | 0 | 158 | |||||
Temporary Equity Liquidation Preference | - | - | 0 | 276 | |||||
Common Stock Par Or Stated Value Per Share | 0 | 0 | 0 | 0 | |||||
Common Stock Shares Authorized | 500 | 500 | 500 | 224 | |||||
Common Stock Shares Issued | 36 | 36 | 32 | 2 | |||||
Shares Outstanding | 36 | 36 | 32 | 2 | |||||
Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables
Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables
Custom Table
Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals
Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals
Interactive Financial Visualizations
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Earnings Market Reaction
| Fiscal Year | Q1 1 Month | Q1 2 Month | Q1 3 Month | Q2 1 Month | Q2 2 Month | Q2 3 Month | Q3 1 Month | Q3 2 Month | Q3 3 Month | Q4 1 Month | Q4 2 Month | Q4 3 Month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 3.24% | 11.91% | -49.51% | - | - | - | - | - | - | - | - | - |
| 2025 | - | - | - | - | - | - | -12.09% | -8.08% | 32.05% | -11.60% | 1.16% | -8.85% |
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial | ||||||||||||
Subscribe to unlock 17+ years of financial data and 90+ calculated metrics
Subscribe to unlock 17+ years of data and 90+ calculated metrics
Performance and Valuation Metrics
Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Insider Transactions
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Institutional Ownership
Evommune, Inc. (EVMN) — SEC Financial Statements & Analysis
Evommune, Inc. (EVMN) is a pharmaceutical preparations company, incorporated in DE. Evommune, Inc. trades on NYSE as: EVMN. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Evommune, Inc. reported a Debt-to-Equity ratio of 0.09x, a Price-to-Sales (P/S) ratio of 36.94x (TTM), a Price-to-Book (P/B) ratio of 1.73x (TTM), at a market cap of $480.24M. Figures below are sourced from SEC EDGAR, as-filed.
- Debt To Equity
- 0.09x
- P/S TTM
- 36.94x
- P/B TTM
- 1.73x
- Market Cap
- $480.24M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Evommune, Inc. in?
Evommune, Inc. (EVMN) operates in the Pharmaceutical Preparations industry.
What is EVMN's market cap?
Evommune, Inc. (EVMN) has a market capitalization of $480.24M as of 2026-06-30.
What exchange does EVMN trade on?
Evommune, Inc. (EVMN) trades on the NYSE.
Where is Evommune, Inc. incorporated?
Evommune, Inc. is incorporated in DE.